Company History

  • October 2013

    Forbes magazine again named China Biologic to its annual list of Asia’s “200 Best Under a Billion.
  • August 2013

    China Biologic repurchased 1,479,704 shares of common stock from one of its individual shareholders for a consideration of $29,594,080.
  • July 2013

    Guizhou Taibang received manufacturing approval certificate for Human Prothrombin Complex Concentrate ("PCC") from China Food and Drug Administration (“CFDA”).
  • June 2013

    Shandong Taibang received the renewed Good Manufacturing Practice ("GMP") certification from China Food and Drug Administration ("CFDA") in respect of its updated plasma production facility.
FirstPage | PreviousPage | NextPage | LastPage CurrentPageIndex:7 [3] [4] [5] [6] [7] [8] [9] [10] [11] 
© 2018 China Biologic Products Holdings, Inc. All Rights Reserved.